XNASSMMT
Market cap13bUSD
Dec 31, Last price
17.85USD
1D
-0.25%
1Q
-8.67%
Jan 2017
108.47%
Name
Summit Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
48.38%
Rev. gr., 5y
165.43%
Revenues
0k
-100.00%
Net income
-615m
L+726.73%
CFO
-77m
L+84.60%
Earnings
Feb 18, 2025
Profile
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑01 | 2018‑01 | 2017‑01 | 2016‑01 | 2015‑01 | |
| Income | ||||||||||
Revenues | 704 -61.07% | |||||||||
Cost of revenue | 89,736 | 81,213 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (89,736) | (80,509) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (946) | (4,401) | ||||||||
Tax Rate | ||||||||||
NOPAT | (88,790) | (76,108) | ||||||||
Net income | (614,928) 726.73% | (74,381) -13.66% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 5,000 | 100,000 | ||||||||
BB yield | -0.31% | -12.17% | ||||||||
| Debt | ||||||||||
Debt current | 2,809 | 21,460 | ||||||||
Long-term debt | 109,389 | 501,756 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,562 | 1,429 | ||||||||
Net debt | (74,044) | 174,609 | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (76,760) | (41,582) | ||||||||
CAPEX | (128) | (624) | ||||||||
Cash from investing activities | (587,774) | (624) | ||||||||
Cash from financing activities | 86,513 | 620,244 | ||||||||
FCF | 201,011 | (367,499) | ||||||||
| Balance | ||||||||||
Cash | 186,242 | 348,607 | ||||||||
Long term investments | ||||||||||
Excess cash | 186,242 | 348,572 | ||||||||
Stockholders' equity | (988,689) | (378,113) | ||||||||
Invested Capital | 1,174,042 | 1,024,959 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 619,646 | 193,336 | ||||||||
Price | 2.61 -38.59% | 4.25 57.99% | ||||||||
Market cap | 1,617,277 96.83% | 821,678 231.16% | ||||||||
EV | 1,543,233 | 996,287 | ||||||||
EBITDA | (87,686) | (77,995) | ||||||||
EV/EBITDA | ||||||||||
Interest | 16,461 | 4,401 | ||||||||
Interest/NOPBT | ||||||||||